Pharmapack Europe 2018 to spotlight new innovations and the young innovators who are shaping the industry

29 Jun 2017
Pharmapack Europe

Pharmapack Europe 2018 (#pharmapackeu), Europe’s dedicated pharmaceutical packaging and drug delivery conference and exhibition, organised by UBM EMEA, is taking place on 7–8 February at Paris Expo Porte de Versailles, Paris. Dedicated to providing industry-leading knowledge and opportunities, Pharmapack is calling for new applications to its Start-up Hub platform and Pharmapack Awards.

Pharmapack Europe is essential for industry insights and networking, and to experience and interact with the latest industry innovations that are reimagining the capabilities of pharmaceutical packaging and drug delivery. The 2018 Start-up Hub will identify young companies as being amongst the most innovative in the industry. Companies in the Start-up Hub will benefit from increased access to potential customers, partners and investors at Pharmapack 2018 from which to forge new and lasting relationships.

Identified start-ups in the inaugural 2017 initiative (www.pharmapackeurope.com/start-hub-2017) spanned the breadth of the industry; from functional inks that incorporate electronic applications into packaging, to needle-free medicine delivery, to an app that scans packages to provide product information, this year’s companies are sure to be equally as innovative and valuable. For 2018 start-ups developing patient-centric packaging or drug delivery solutions in line with connected health and anti-counterfeiting measures are encouraged to apply. If you are interested in exhibiting, visit www.pharmapackeurope.com/start-up-hub to learn more and download the application form.

Pharmapack Awards

A long-standing highlight that embodies the ethos of the conference and exhibition, the prestigious Pharmapack Awards, also returns in 2018. The awards consist of two categories; the Exhibitor Innovation category and, for non-exhibitors, the Health Product category. Exhibitors that take part in the Innovation Gallery automatically enter the Awards for this category, but will still need to complete an entry document for a chance to win.

Exhibitor Innovation winners in 2017 (www.pharmapackeurope.com/innovation/awards-winners-2017) provided new approaches to some of the biggest challenges, including reducing vial overfill and intuitive packaging that increases adherence. The Health Product category distinguishes innovative packaging of new health products or improved packaging of an existing health product (for human or veterinary use), that has created a tangible benefit for users and administrators. The 2017 award winners used innovative packaging design to improve patient compliance and reduce environmental footprint, respectively.

Pharmapack Award applications are now open for 2018 to companies providing new products set to shape the future of the industry. These awards shine a light on the companies and products that sit at the centre of the industry. Pharmapack Europe was delighted to recently be shortlisted for a prestigious AEO Excellence Award for Sustainability, and particularly encourages entries from companies that are making packaging and drug delivery devices more sustainable, smarter, more effective, and more valuable to users.

Applications for the 2018 Pharmapack Awards are open until 3 November, 2017 and will be assessed by some of the industry’s leading figures globally, providing a powerful endorsement. For more information please visit:

Exhibitor Innovations: www.pharmapackeurope.com/innovation/exhibitor-innovations

Personalised medicines, intelligent packaging and FDA deadlines seen as major trends for pharma packaging in 2018

Europe’s biggest pharma packaging and drug delivery exhibition and conference highlighted upcoming trends in the industry with experts delivering an in-depth media debate focusing on smart and intelligent packaging, the increasing role that the internet has on the industry, and the potential implications of upcoming regulatory changes.

Trends in prefilled drug delivery devices

Modern patients want therapies that are effective and convenient to take. Someone who needs a medicine daily is more likely to comply with the treatment if the drug in question is easy to administer in the comfort of their own home. This patient demand, combined with drug industry interest in lowering costs, advances in materials development and growth of the biologic drug sector, is fuelling expansion of the prefilled drug delivery device market.

The future is now – Pharmapack Europe 2018 to showcase evolution and revolution in packaging and drug delivery

Pharmapack Europe 2018 (#pharmapackeu) today announced the comprehensive event programme for Europe’s dedicated pharmaceutical packaging and drug delivery conference and exhibition taking place on 7–8 February at Paris Expo Porte de Versailles, Paris. The packed event programme includes key note speeches from leading industry figures, a symposium, educational workshops, and a learning lab that will explore regulatory changes and impacts, challenges in packaging & devices development: biologics, materials, sustainability and quality consistency, and how new patient-centric innovations in drug delivery will revolutionise lives and improve treatment adherence.

PharmaPack interviews Dr. Rolf Abelmann, Managing Director of IVM about CRP

Child-resistant packaging, is designed to prevent young children from ingesting products that could be harmful or toxic. CRP is a growing area in packaging with analysts' forecast that expect +7.4% growth over the next 5 years. PharmaPack interviews Dr. Rolf Abelmann, Managing Director of IVM (Institut VerpackungsMarktforschung GmbH) to find out more.

The challenges of packaging biologics

Biologics are a huge growth area and promise many groundbreaking new treatments in the future. But their radical difference from traditional drugs raises some unique challenges in terms of packaging and delivery systems.

Serialisation improves public health

All pharmaceutical companies selling drugs in the US must be partially compliant with the FDA serialisation regulations since January 2015. And since the beginning of 2017 all drugs sold in the EU must comply with the EU ‘Falsified Medicines Directive’. These measures will help pharmaceutical companies better identify defective drugs as well as counterfeit pharmaceuticals that pose a serious danger to public health.